Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database - Top-Institutions - MDSpire

Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database

  • By

  • Bo Cao

  • Mingfeng Shen

  • Chenchen Du

  • Qiuping Song

  • Zhongjie Ma

  • June 16, 2026

  • 0 min

Share

Top Institutions in Obgyn

Brief introduction explaining scope and methodology.

  • #1

    UCSF–Stanford Center of Excellence in Regulatory Science and Innovation (CERSI)
    UCSF–Stanford Center of Excellence in Regulatory Science and Innovation (CERSI)

    San Francisco, California

    Key Differentiators

    • Pharmacovigilance
    • Pharmacoepidemiology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Pharmacoepidemiology
    • Drug Safety

  • #3

    Uppsala Monitoring Centre
    Uppsala Monitoring Centre

    Uppsala, Sweden

    Key Differentiators

    • Pharmacovigilance

  • #4

    Tohoku Medical Megabank Organization
    Tohoku Medical Megabank Organization

    Sendai, Japan

    Key Differentiators

    • Pharmacoepidemiology

  • #5

    French Reference Centre for Teratogenic Agents
    French Reference Centre for Teratogenic Agents

    Paris, France

    Key Differentiators

    • Teratology
    • Pharmacology

Original Source(s)

Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database

  • by Bo Cao, Mingfeng Shen, Chenchen Du, Qiuping Song, Zhongjie Ma

  • June 16, 2026

Related Content

The U.S. infant mortality rate fell to an all-time low, though it still trails other similar nations

Millimeter-Wave MIMO radar for contactless neonatal heart-rate assessment: performance under common resuscitation-related maneuvers and feasibility in clinical workflow

State Choices, Unequal Access: Policies Shaping Reproductive Health Care Across the United States